Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] AOCI Attributable to Parent [Member] Long-Term Debt, Type [Axis] Secured Note [Member] Related Party [Axis] Investor [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Note Purchase Agreement [Member] Investor Note 1 [Member] Investor Note 2 [Member] Note Purchase Agreement 2 [Member] Legal Entity [Axis] Ascendiant Capital Partners L L C [Member] Note Purchase Agreement 3 [Member] Class of Stock [Axis] Award Type [Axis] Warrant [Member] Antidilutive Securities [Axis] Options Held [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS Current assets: Cash Prepaid expenses and other receivables Accounts receivable - related party Inventory Total current assets Property and equipment, net of accumulated depreciation Intangible assets, net of accumulated amortization Total other assets Total assets LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY Current liabilities: Accounts payable Other liabilities and accrued expenses Foreign currency contract Due to related party Notes payable, current portion Deferred revenue Total current liabilities Notes payable, net of current portion Deferred revenue, net of current portion Total liabilities Commitments and contingencies Stockholders’ (deficit) equity: Common stock, $0.001 par value, 42,000,000 shares authorized and 24,102,866 shares issued and outstanding at September 30, 2022 and March 31, 2022 Additional paid-in capital Accumulated deficit Accumulated other comprehensive loss Total stockholders’ (deficit) equity Total liabilities and stockholders’ (deficit) equity Common stock, par value per share Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Sales Cost of Sales Gross Profit Operating expenses: Research and development General and administrative Total operating expenses Loss from operations Interest expense Net loss Other comprehensive loss: Foreign currency translation adjustment Comprehensive loss Net loss per share, basic and diluted Weighted average number of shares outstanding, basic and diluted Statement [Table] Statement [Line Items] Beginning balance, value Beginning Balance, Shares Exercise of warrants Exercise of warrants, shares Foreign currency translation adjustment Net loss Ending balance, value Ending Balance, Shares Statement of Cash Flows [Abstract] Cash Flows From Operating Activities: Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Amortization of debt discount Change in fair value of foreign currency contract Changes in assets and liabilities: Prepaid expenses and other receivables Inventory Accounts payable Due to (from) related parties Other liabilities and accrued expenses Deferred revenue Net cash used in operating activities Cash Flows From Investing Activities: Capitalized patent costs Capitalized software development costs Purchase of property and equipment Net cash used in investing activities Cash Flows From Financing Activities: Proceeds from issuance of notes payable Proceeds from warrant exercise Repayments of note payable Net cash used in financing activities Effect of exchange rate changes on cash Net decrease in cash Cash at beginning of period Cash at end of period Supplemental disclosure of non-cash financing activities: Release of prepayment from equity compensation Monitoring fees added to notes payable  Accounting Policies [Abstract] ORGANIZATION AND PRINCIPAL ACTIVITIES BASIS OF PRESENTATION Commitments and Contingencies Disclosure [Abstract] LICENSING AGREEMENTS Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Debt Disclosure [Abstract] NOTES PAYABLE Equity [Abstract] STOCKHOLDERS’ (DEFICIT) EQUITY Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] OTHER ITEMS Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of presentation Use of Estimates Cash and Cash Equivalents Revenue Recognition Intangible Assets Share-Based Payments Income Taxes Recently adopted accounting pronouncements Schedule of Related Party Transactions Schedule of long term debt Schedule of earnings (loss) per share Accumulated deficit Cash Cash and cash equivalents Non-refundable, upfront cash payment Deferred revenue Amounts due to related parties at beginning of period Amounts invoiced by Pharma to DDL Amounts invoiced by DDL to Pharma Amounts paid by DDL to Pharma Foreign exchange differences Amounts due from / to related parties at end of period 2022 2023 Capital Leases, Future Minimum Payments, Receivable Thereafter Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Line Items] Principal amount Original issue discount Legal fees Commission expense Proceeds from note payable Monitoring fee, percentage Agreed to pay Commission expenses Purchase Price Amount paid in cash Net loss attributable to common stockholders Weighted average basic and diluted shares outstanding Basic and diluted loss per share: Schedule of Stock by Class [Table] Class of Stock [Line Items] Warrants exercised Number of shares issued Proceeds from warrants Warrant Outstanding Warrants to purchase Options issued to purchase units Anti-dilutive common stock Subsequent Event [Table] Subsequent Event [Line Items] Maturity date Notes payable Redemption amount Assets, Current Other Assets, Noncurrent Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Cost of Goods and Services Sold Gross Profit Operating Expenses Operating Income (Loss) Net Income (Loss) Attributable to Parent Shares, Outstanding OCI, Foreign Currency Transaction and Translation Gain (Loss), Arising During Period, Tax Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Inventories Increase (Decrease) in Accounts Payable Increase (Decrease) in Due from Related Parties Increase (Decrease) in Other Accrued Liabilities Increase (Decrease) in Deferred Revenue Net Cash Provided by (Used in) Operating Activities Payments to Acquire Intangible Assets Payments to Develop Software Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Repayments of Notes Payable Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash [Default Label] Deferred Revenue